European Biotechnology Magazine

Not only antibody also a oral drug to inhibit complement system is in development and attracts millions in funding to InflarX

As Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company … more ➔

Venture Capital

Scarlet raises £3.2 million to advance lab-grown red blood cell therapies

Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have … more ➔

Bayer

For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies

Bayer AG is strengthening its ophthalmology portfolio with the acquisition of Perfuse Therapeutics for up to $2.45bn. The focus is on a Phase II candidate for glaucoma and diabetic retinopathy with potential … more ➔

Report

Switzerland’s biotech sector defies tough markets with record revenue

If one follows the figures in the Swiss Biotech Report 2026, the green lights are more prominent than the red warning signals. The Swiss biotech industry continued its growth momentum in 2025 and even … more ➔

Example of fitting a macrocycle molecule to a pocket of interest

Sevan Habeshian & Christian Heinis et al. https://www.nature.com/articles/s41467-022-31428-

Drug Design

Macrocycles: big is the new beautiful

In the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators continually strive to develop therapies that are both highly selective and clinically effective, … more ➔

European Biotechnology

1 / 4

10/3/26 mw: Satz, PDF an JE, danach zu Andi

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

2 / 4

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

3 / 4

Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔

Get a free sample copy | Abo

4 / 4

This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … more ➔

Get a free sample copy | Abo

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here